论文部分内容阅读
Objective:In order to evaluate potential application for diagnosis and prognosis of non-small cell lung cancer (NSCLC),as well as to determine its role in the pathogenesis of the disease,we prepared anti-human hnRNP A2/B1 polyclonal antibody.Methods:Prokaryotic expression vector of pET28a(+)-hnRNP A2/B1 was constructed and transformed into E.coli BL21.The recombinant protein induced by IPTG was purified and injected to rabbits for antibody preparation.Expression of hnRNP A2/B1 was examined in 45 tissues of NSCLC and 16 inflammatory pseudotumor tissues of lung by immunohistochem- istry with the antibody.The commercial hnRNP A2/B1 monoclonal antibody was used as a control.Results:(1)Polyclonal an- tibody against hnRNP A2/B1 with high title was obtained.(2)The positive staining in NSCLC tissues was 62.22%,which was substantially higher than that in normal tissues(40%,P=0.035)or inflammatory pseudotumor tissues(31.25%,P=0.033). (3)Expression of hnRNP A2/B1 positively correlated with age and the history of smoking,whereas it negatively correlated with differentiation staging of tumors.(4)Follow-up study showed that the survival time of patients with positive staining was significantly shorter than that of patients without hnRNP A2/B1 expression(P=0.048).Conclusion:It is successful to make the recombinant protein and prepare the polyclonal antibody agonist human hnRNP A2/B1.It may be a valuable marker for the diagnosis and prognosis of NSCLC.Our results provide a basis for further study in clinical application.
Objective: In order to evaluate potential application for diagnosis and prognosis of non-small cell lung cancer (NSCLC), as well as determine its role in the pathogenesis of the disease, we prepared anti-human hnRNP A2 / B1 polyclonal antibody. Methods : Prokaryotic expression vector of pET28a (+) - hnRNP A2 / B1 was constructed and transformed into E. coli BL21. The recombinant protein induced by IPTG was purified and injected to rabbits for antibody preparation. Expression of hnRNP A2 / B1 was examined in 45 tissues of NSCLC and 16 inflammatory pseudotumor tissues of lung by immunohistochemistry with the antibody. commercial hnRNP A2 / B1 monoclonal antibody was used as a control. Results: (1) Polyclonal an- tibody against hnRNP A2 / B1 with high title was (2) The positive staining in NSCLC tissues was 62.22%, which was substantially higher than that in normal tissues (40%, P = 0.035) or inflammatory pseudotumor tissues (31.25%, P = 0.033) hnRNP A2 / B1 positively correlated with age an d the history of smoking, yet it negatively correlated with differentiation staging of tumors. (4) Follow-up study showed that survival time of patients with positive staining was significantly shorter than that of patients without hnRNP A2 / B1 expression (P = 0.048 ) .Conclusion: It is successful to make the recombinant protein and prepare the polyclonal antibody agonist human hnRNP A2 / B1.It may be a valuable marker for the diagnosis and prognosis of NSCLC. Our results provide a basis for further study in clinical application.